BioAtla (BCAB) Total Current Liabilities (2020 - 2026)
BioAtla (BCAB) posted quarterly Total Current Liabilities of $20.7 million for Q1 2026, up 29.28% year-over-year from $16.0 million in Q1 2025, and down 5.61% quarter-over-quarter from $21.9 million in Q4 2025.
BioAtla (BCAB) Total Current Liabilities (2020 - 2026) Analysis & Trends
BioAtla's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $20.7 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 29.28% year-over-year to $20.7 million; the TTM figure through Mar 2026 stood at $20.7 million (up 29.28% YoY), while the FY2025 annual figure was $21.9 million, up 50.77% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $20.7 million, down from $21.9 million in the prior quarter.
- The five-year high for Total Current Liabilities was $35.6 million in Q3 2023, with the low at $14.5 million in Q4 2024.
- The 5-year median for Total Current Liabilities is $20.7 million (2026), against an average of $22.2 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities surged 52.78% in 2023, then tumbled 48.7% in 2024.
- BioAtla's Total Current Liabilities stood at $23.1 million in 2022, then increased by 22.54% to $28.3 million in 2023, then sank by 48.7% to $14.5 million in 2024, then soared by 50.77% to $21.9 million in 2025, then slipped by 5.61% to $20.7 million in 2026.
- Business Quant data shows BCAB's Total Current Liabilities at $20.7 million in Q1 2026, $21.9 million in Q4 2025, and $18.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 21.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.02 Mn |
| Mar 31, 2026 | 20.69 Mn |
| Dec 31, 2025 | 21.92 Mn |
| Sep 30, 2025 | 17.98 Mn |
| Jun 30, 2025 | 16.60 Mn |
| Mar 31, 2025 | 16.01 Mn |
| Dec 31, 2024 | 14.54 Mn |
| Sep 30, 2024 | 19.46 Mn |
| Jun 30, 2024 | 17.46 Mn |
| Mar 31, 2024 | 19.26 Mn |
| Dec 31, 2023 | 28.34 Mn |
| Sep 30, 2023 | 35.60 Mn |
| Jun 30, 2023 | 33.65 Mn |
| Mar 31, 2023 | 26.26 Mn |
| Dec 31, 2022 | 23.13 Mn |
| Sep 30, 2022 | 23.83 Mn |
| Jun 30, 2022 | 25.51 Mn |
| Mar 31, 2022 | 17.19 Mn |
| Dec 31, 2021 | 19.81 Mn |
| Sep 30, 2021 | 45.23 Mn |